Vanda Pharmaceuticals Inc. (VNDA) Financial Ratios
22 years of historical data (2004–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
N/A
—
5yr avg: 25.88
30Y Low19.0·High53.7
P/FCF
↑
N/A
—
5yr avg: 15.68
30Y Low1.9·High39.6
P/B Ratio
↓
1.15
+12% vs avg
5yr avg: 1.02
30Y Low0.3·High23.3
ROE
↓
-50.9%
↑-456% vs avg
5yr avg: -9.2%
30Y Low-221%·High34%
Debt/EBITDA
↑
N/A
—
5yr avg: 0.75
30Y Low0.3·High1.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VNDA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Vanda Pharmaceuticals Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $378M | $520M | $279M | $243M | $421M | $893M | $725M | $900M | $1.4B | $680M | $693M |
| Enterprise Value | $305M | $448M | $189M | $116M | $297M | $853M | $678M | $870M | $1.3B | $646M | $653M |
| P/E Ratio → | -1.71 | — | — | 96.79 | 67.18 | 27.05 | 31.29 | 7.78 | 54.44 | — | — |
| P/S Ratio | 1.75 | 2.41 | 1.40 | 1.26 | 1.66 | 3.32 | 2.92 | 3.96 | 7.18 | 4.12 | 4.75 |
| P/B Ratio | 1.15 | 1.59 | 0.52 | 0.45 | 0.80 | 1.77 | 1.60 | 2.19 | 5.03 | 5.18 | 5.28 |
| P/FCF | — | — | — | 19.56 | 13.45 | 14.03 | 14.51 | 20.03 | 300.15 | — | — |
| P/OCF | — | — | — | 18.97 | 13.17 | 13.91 | 14.01 | 19.59 | 46.22 | — | — |
P/E links to full P/E history page with 30-year chart
VNDA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.07 | 0.95 | 0.60 | 1.17 | 3.18 | 2.73 | 3.83 | 6.86 | 3.92 | 4.47 |
| EV / EBITDA | — | — | — | — | 32.80 | 18.96 | 22.52 | 33.83 | 53.66 | — | — |
| EV / EBIT | — | — | — | — | 46.96 | 20.24 | 21.41 | 38.12 | 60.96 | — | — |
| EV / FCF | — | — | — | 9.38 | 9.49 | 13.41 | 13.56 | 19.35 | 286.94 | — | — |
VNDA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Vanda Pharmaceuticals Inc. earns an operating margin of -70.0%. Operating margins have compressed from -7.2% to -70.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -50.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 94.0% | 94.0% | 94.3% | 92.3% | 90.5% | 90.5% | 90.6% | 89.2% | 89.4% | 89.2% | 83.1% |
| Operating Margin | -70.0% | -70.0% | -20.5% | -7.2% | 2.5% | 15.7% | 11.0% | 10.0% | 11.3% | -10.2% | -12.7% |
| Net Profit Margin | -102.0% | -102.0% | -9.5% | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% | -9.4% | -12.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -50.9% | -50.9% | -3.5% | 0.5% | 1.2% | 6.9% | 5.4% | 33.7% | 12.4% | -11.9% | -13.6% |
| ROA | -38.5% | -38.5% | -2.9% | 0.4% | 1.0% | 5.9% | 4.6% | 28.3% | 9.4% | -7.5% | -8.5% |
| ROIC | -32.2% | -32.2% | -7.0% | -2.5% | 1.1% | 7.3% | 5.2% | 5.8% | 10.4% | -13.4% | -16.1% |
| ROCE | -33.6% | -33.6% | -7.3% | -2.5% | 1.2% | 8.5% | 6.1% | 6.5% | 10.5% | -11.5% | -11.5% |
VNDA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $85M exceeds total debt of $13M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | 1.23 | 0.27 | 0.45 | 0.57 | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.17 | -0.23 | -0.23 | -0.08 | -0.10 | -0.07 | -0.22 | -0.26 | -0.31 |
| Net Debt / EBITDA | — | — | — | — | -13.67 | -0.88 | -1.58 | -1.19 | -2.47 | — | — |
| Debt / FCF | — | — | — | -10.18 | -3.96 | -0.62 | -0.95 | -0.68 | -13.21 | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($85M) exceeds total debt ($13M)
VNDA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Vanda Pharmaceuticals Inc.'s current ratio of 2.39x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.94x to 2.39x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.39 | 2.39 | 4.39 | 4.94 | 5.68 | 6.43 | 6.21 | 5.95 | 5.64 | 2.41 | 3.46 |
| Quick Ratio | 2.38 | 2.38 | 4.37 | 4.92 | 5.67 | 6.41 | 6.19 | 5.93 | 5.62 | 2.40 | 3.45 |
| Cash Ratio | 1.82 | 1.82 | 3.75 | 4.43 | 5.11 | 5.82 | 5.58 | 5.25 | 4.85 | 2.04 | 2.81 |
| Asset Turnover | — | 0.44 | 0.30 | 0.30 | 0.40 | 0.45 | 0.47 | 0.47 | 0.58 | 0.80 | 0.69 |
| Inventory Turnover | 7.04 | 7.04 | 6.56 | 10.90 | 20.34 | 25.00 | 18.25 | 21.48 | 20.63 | 21.25 | 31.72 |
| Days Sales Outstanding | — | 92.18 | 86.49 | 64.71 | 48.08 | 44.11 | 44.18 | 42.36 | 54.40 | 38.92 | 50.66 |
VNDA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Vanda Pharmaceuticals Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 1.0% | 1.5% | 3.7% | 3.2% | 12.9% | 1.8% | — | — |
| FCF Yield | — | — | — | 5.1% | 7.4% | 7.1% | 6.9% | 5.0% | 0.3% | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $59M | $58M | $58M | $57M | $57M | $55M | $55M | $53M | $45M | $43M |
Peer Comparison
Compare VNDA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VNDAYou | $378M | -1.7 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 SUPN | $3B | -76.9 | 53.4 | 65.5 | 89.6% | -5.1% | -3.7% | -2.8% | 0.7 |
 PTCT | $5B | 8.3 | 5.4 | 7.6 | 95.9% | 49.5% | — | — | 0.5 |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 AVPT | $2B | 68.8 | 44.8 | 27.3 | 74.1% | 7.9% | 9.4% | 1143.3% | 0.3 |
 AXSM | $11B | -59.8 | — | — | 92.6% | -26.5% | -252.1% | -1906.7% | — |
 INTR | $3B | 11.4 | 17.3 | 4.9 | 42.4% | 10.9% | 13.2% | 3.9% | 15.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See VNDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VNDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VNDA vs SUPN
Side-by-side business, growth, and profitability comparison vs Supernus Pharmaceuticals, Inc..
Start ComparisonVNDA — Frequently Asked Questions
Quick answers to the most common questions about buying VNDA stock.
What is Vanda Pharmaceuticals Inc.'s P/E ratio?
Vanda Pharmaceuticals Inc.'s current P/E ratio is -1.7x. The historical average is 43.5x.
What is Vanda Pharmaceuticals Inc.'s ROE?
Vanda Pharmaceuticals Inc.'s return on equity (ROE) is -50.9%. The historical average is -42.4%.
Is VNDA stock overvalued?
Based on historical data, Vanda Pharmaceuticals Inc. is trading at a P/E of -1.7x. Compare with industry peers and growth rates for a complete picture.
What are Vanda Pharmaceuticals Inc.'s profit margins?
Vanda Pharmaceuticals Inc. has 94.0% gross margin and -70.0% operating margin.